Mental health service usage ‐ not measured · improving mental health and wellbeing
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects of MHFA ‐ not measured · improving mental health and wellbeing
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Individual mental health ‐ not measured · improving mental health and wellbeing
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental health service usage ‐ not measured · improving mental health and wellbeing
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects of MHFA ‐ not measured · improving mental health and wellbeing
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Individual mental health ‐ not measured · improving mental health and wellbeing
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental health service usage ‐ not measured · improving mental health and wellbeing
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects of MHFA ‐ not measured · improving mental health and wellbeing
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · children and adolescents (< 18 years of age) with first‐line ALL
1 finding from 1 review
Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in event‐free survival compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (moderate certainty).
1 finding from 1 review
Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in hypersensitivity compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in pancreatitis compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in thromboembolism compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in osteonecrosis compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in asparaginase‐associated toxicity compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).
1 finding from 1 review
FEV1 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
QoL · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Survival · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found